Biomea Fusion (NASDAQ: BMEA) — Perfil da empresa, notícias e dados financeiros
Biomea Fusion is a biotech company developing covalent small molecules for cancer treatment aimed at improving patient outcomes.

Biomea Fusion
Biomea Fusion (NASDAQ:BMEA) is a dynamic biotech company focused on discovering and developing innovative treatments for patients battling cancer and other grave diseases. Their projects primarily involve the investigation of novel covalent small molecules that can potentially offer transformative outcomes in the field of oncology and beyond. With a commitment to advancing science and improving lives, Biomea Fusion's objectives encompass the successful progression of their drug candidates through clinical trials, aiming for breakthrough therapies that can meaningfully improve patient outcomes. At the heart of their operations is a dedication to leveraging cutting-edge science to address unmet medical needs, identifying and targeting critical pathways in disease mechanisms.
Resumo
Operações
Produtos e/ou serviços de Biomea Fusion
- Covalent menin inhibition technology, targeting a range of cancers.
- BMF-219, an oral small molecule, focused on difficult-to-treat cancers.
- Preclinical programs studying the potential in a variety of solid and hematologic malignancies.
- Collaborations aimed at advancing precision oncology treatments.
- Research into the molecular drivers of disease to inform future therapies.
- Development of biomarker-driven approaches to match patients with the most effective treatments.
equipe executiva do Biomea Fusion
- Michael J. M. HitchcockInterim CEO & Director
- Ramses M. ErdtmannCo-Founder, President, COO & Director
- Heow TanChief Technical & Quality Officer
- Caroline Perez- DupontSenior Vice President of Legal
- Thorsten KirschbergExecutive Vice President of Research
- Stephan MorrisChief Development Officer
- Ravi UpasaniExecutive Vice President of Intellectual Property
Principais indicadores financeiros
Resultados divulgados pela Biomea Fusion, em USD.
- Cap. de mercado
- 46,9 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -81,3 mi | -61,8 mi | |
| 0 | -144,1 mi | -138,4 mi | |
| 0 | -126,1 mi | -117,3 mi | |
| 0 | -83,6 mi | -80 mi |